In light of recent evidence that indicates the potential differences in BRCA1 vs. BRCA2-mutated cancers, we further tested if tumours with Brca1 and Brca2 deficiencies respond differently to treatment by analyzing how the Brca status of ovarian tumours influence the TME composition and response to therapy. The gene discussed is BRCA2; the disease is ovarian neoplasm.